v3.26.1
Acquisitions (Details)
$ / shares in Units, $ in Thousands, € in Millions
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Aug. 03, 2026
$ / shares
Jul. 21, 2025
USD ($)
Apr. 01, 2025
USD ($)
Jul. 03, 2024
USD ($)
Jul. 03, 2024
EUR (€)
Jul. 02, 2024
USD ($)
Jun. 27, 2024
EUR (€)
Jun. 15, 2024
USD ($)
LicensedAsset
Jan. 08, 2024
USD ($)
Apr. 30, 2026
USD ($)
Nov. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
shares
Jun. 30, 2025
USD ($)
Sep. 30, 2024
USD ($)
shares
Jun. 30, 2026
USD ($)
shares
Jun. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
shares
Dec. 31, 2024
USD ($)
Mar. 06, 2024
$ / shares
shares
Jan. 22, 2024
$ / shares
shares
Asset Acquisition [Line Items]                                        
Additional cash payment required                       $ 65,041     $ 65,041   $ 94,339      
Research and development                       $ 38,202 $ 45,489   $ 77,581 $ 81,803        
Radiopharm Theranostics Limited                                        
Asset Acquisition [Line Items]                                        
Shares owned (in shares) | shares                       537,958,513   149,625,180 537,958,513          
Shares Purchase (in shares) | shares                                 388,333,333      
Purchase amount in investment in equity securities                           $ 5,000     $ 10,000      
Perspective Therapeutics, Inc                                        
Asset Acquisition [Line Items]                                        
Subsidiary, ownership percentage, noncontrolling owner                                     19.90%  
Shares owned (in shares) | shares                       11,677,339     11,677,339          
Perspective Therapeutics, Inc | Licenses                                        
Asset Acquisition [Line Items]                                        
Acquisition of exclusive license option                 $ 28,000                      
Perspective Therapeutics, Inc, Fully Diluted Basis                                        
Asset Acquisition [Line Items]                                        
Subsidiary, ownership percentage, noncontrolling owner                                     17.35%  
Perspective Common Stock                                        
Asset Acquisition [Line Items]                                        
Shares acquired (in shares) | shares                                     60,431,039 56,342,355
Percentage of acquired interest                                       11.39%
Share price (in dollars per share) | $ / shares                                     $ 0.95 $ 0.37
Evergreen Theragnostics                                        
Asset Acquisition [Line Items]                                        
Payments to acquire businesses     $ 276,400                                  
Additional cash payment required     25,000                                  
Acquisition and integration related costs                       $ 0 $ 14,700   $ 1,900 $ 17,200        
Payment of transaction expenses     11,600                                  
Nonrecurring post combination expense                             7,500          
Component of consideration transferred     $ 6,100                                  
Business Combination, Separately Recognized Transaction, Acquisition-Related Cost, Expensed, Statement of Income or Comprehensive Income [Extensible Enumeration]     Operating Expenses Before Gain Loss On Sale Of Assets                                  
Pre existing debt     $ 4,300                                  
Agreement and Plan of Merger with Curium Pharma | Subsequent Event                                        
Asset Acquisition [Line Items]                                        
Share price (in dollars per share) | $ / shares $ 102.5                                      
Date of Merger Agreement Aug. 03, 2026                                      
Additional Milestone Payments | Evergreen Theragnostics                                        
Asset Acquisition [Line Items]                                        
Additional cash payment required     $ 727,500                                  
Regulatory Milestones | RM2 Sublicense Agreement [Member]                                        
Asset Acquisition [Line Items]                                        
Payment for acquisitions | €             € 10.0                          
Radiopharm Theranostics Limited                                        
Asset Acquisition [Line Items]                                        
Payment for acquisitions               $ 2,000                        
Asset acquisition, additional milestone payments               $ 20,000                        
Number of licensed asset acquired | LicensedAsset               2                        
Radiopharm Theranostics Limited | Sales Milestones                                        
Asset Acquisition [Line Items]                                        
Asset acquisition, additional milestone payments               $ 6,500                        
Life Molecular Imaging, RM2 Technology                                        
Asset Acquisition [Line Items]                                        
Research and development                                 11,200 $ 36,000    
Payment for acquisitions       $ 35,000   $ 1,000                            
Contingent regulatory and development milestones maximum amount | €         € 45.0                              
Contingent regulatory and development milestones minimum amount | €         82.5                              
Life Molecular Imaging, RM2 Technology | Sales Milestones                                        
Asset Acquisition [Line Items]                                        
Asset acquisition, additional milestone payments | €         280.0                              
Life Molecular Imaging, RM2 Technology | Regulatory Milestones                                        
Asset Acquisition [Line Items]                                        
Asset acquisition, additional milestone payments | €         € 127.5                              
Lantheus Biosciences Ltd                                        
Asset Acquisition [Line Items]                                        
Acquisition and integration related costs                       $ 1,900     3,800   $ 36,700      
Payment for acquisitions   $ 355,200                                    
Payment of working capital settlement in business combination                     $ 2,300                  
Additional working capital settlement received                   $ 300                    
Total adjustments to purchase consideration                             $ 2,600          
Asset acquisition, additional milestone payments   $ 400,000